Wall Street analysts forecast that Agenus Inc (NASDAQ:AGEN) will post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.37). Agenus posted earnings of ($0.30) per share during the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.16) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.07). For the next year, analysts expect that the business will post earnings of ($1.36) per share, with EPS estimates ranging from ($1.37) to ($1.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The business’s revenue was down 24.4% on a year-over-year basis.
In related news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were acquired at an average price of $3.55 per share, for a total transaction of $355,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Karen Valentine sold 8,358 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the transaction, the insider now owns 109,879 shares in the company, valued at approximately $380,181.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,514 shares of company stock worth $70,978. 7.60% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Alliancebernstein L.P. grew its stake in Agenus by 15.1% in the 2nd quarter. Alliancebernstein L.P. now owns 144,700 shares of the biotechnology company’s stock valued at $566,000 after buying an additional 19,000 shares during the last quarter. Wells Fargo & Company MN grew its stake in Agenus by 11.4% in the 2nd quarter. Wells Fargo & Company MN now owns 520,142 shares of the biotechnology company’s stock valued at $2,033,000 after buying an additional 53,343 shares during the last quarter. Northern Trust Corp grew its stake in Agenus by 4.1% in the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after buying an additional 37,239 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Agenus by 511.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 74,407 shares during the last quarter. Finally, Artal Group S.A. grew its stake in Agenus by 25.0% in the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 37.87% of the company’s stock.
Agenus (NASDAQ:AGEN) traded down $0.01 during trading on Friday, hitting $3.51. 551,275 shares of the stock traded hands, compared to its average volume of 854,605. The firm has a market cap of $352.64, a price-to-earnings ratio of -3.00 and a beta of 2.11. Agenus has a one year low of $3.20 and a one year high of $5.45. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/06/0-28-eps-expected-for-agenus-inc-agen-this-quarter.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.